Alumis (ALMS) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Alumis (NASDAQ: ALMS):

• 1/21/2026 – Alumis is now covered by analysts at Chardan Capital. They set a “buy” rating and a $37.00 price target on the stock.
• 1/21/2026 – Alumis was given a new $37.00 price target on by analysts at Loop Capital.
• 1/21/2026 – Alumis is now covered by analysts at Chardan Capital. They set a “buy” rating and a $37.00 price target on the stock.
• 1/21/2026 – Alumis is now covered by analysts at Chardan Capital. They set a “buy” rating and a $37.00 price target on the stock.
• 1/9/2026 – Alumis had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock, up previously from $20.00.
• 1/7/2026 – Alumis had its price target raised by analysts at Morgan Stanley from $22.00 to $33.00. They now have an “overweight” rating on the stock.
• 1/7/2026 – Alumis had its price target raised by analysts at Guggenheim from $18.00 to $32.00. They now have a “buy” rating on the stock.
• 1/6/2026 – Alumis had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 1/6/2026 – Alumis had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $50.00 price target on the stock.
• 1/6/2026 – Alumis had its price target raised by analysts at Leerink Partners from $20.00 to $32.00. They now have an “outperform” rating on the stock.
• 1/6/2026 – Alumis had its “outperform” rating reaffirmed by analysts at UBS Group AG.
• 1/6/2026 – Alumis had its price target raised by analysts at Wells Fargo & Company from $17.00 to $39.00. They now have an “overweight” rating on the stock.
• 12/29/2025 – Alumis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Alumis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/18/2025 – Alumis had its price target raised by analysts at HC Wainwright from $14.00 to $20.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Alumis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Alumis had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Alumis was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Insider Activity

In other news, major shareholder Foresite Capital Management Vi acquired 411,764 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was bought at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the acquisition, the insider owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This represents a 7.78% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director James B. Tananbaum purchased 411,764 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was acquired at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the purchase, the director owned 5,702,536 shares in the company, valued at $96,943,112. This represents a 7.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 4,612,402 shares of company stock worth $49,352,316 in the last ninety days. Corporate insiders own 40.70% of the company’s stock.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.